Effect of the dipeptidyl peptidase-4 inhibitor linagliptin on atherosclerotic lesions in Watanabe heritable hyperlipidemic rabbits: iMap-IVUS and pathological analysis-Reference-Cited by-同舟云学术

Effect of the dipeptidyl peptidase-4 inhibitor linagliptin on atherosclerotic lesions in Watanabe heritable hyperlipidemic rabbits: iMap-IVUS and pathological analysis

Published:2020-09-10 Issue:1 Volume:36 Page:127-135
ISSN:0910-8327
Container-title:Heart and Vessels
language:en
Short-container-title:Heart Vessels

Author:

Kurosawa Takafumi,Li Yuxin^ORCID,Sudo Mitsumasa,Haruta Hironori,Hagikura Kazuhiro,Takayama Tadateru,Hiro Takafumi,Shiomi Masashi,Hao Hiroyuki,Matsumoto Taro,Hirayama Atsushi,Okumura Yasuo

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00380-020-01689-8.pdf

Reference22 articles.

1. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837–853

2. ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ (2010) Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363(3):233–244

3. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32(1):193–203

4. Anderson RJ, Bahn GD, Moritz TE, Kaufman D, Abraira C, Duckworth W; VADT Study Group (2011) Blood pressure and cardiovascular disease risk in the veterans affairs diabetes trial. Diabetes Care 34(1):34–38

5. Zhong J, Kankanala S, Rajagopalan S (2016) Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies. Curr Opin Lipidol 27(5):484–492

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dipeptidyl peptidase-4 inhibitors reduce the incidence of first cardiovascular events in Japanese diabetic patients;Heart and Vessels;2023-07-31

2. Novel ultrasound techniques in the identification of vulnerable plaques—an updated review of the literature;Frontiers in Cardiovascular Medicine;2023-05-24